报告题目：随生理信号响应的智能递药系统Leverage Physiologyfor Bioresponsive Drug Delivery

报 告 人：Zhen Gu, PhD，Professor

单  位：美国加州大学洛杉矶分校Universityof California, Los Angeles (UCLA)

时  间：2018年7月12日下午14：00 

地  点：材料学科楼413会议室

报告摘要：

Spurredby recent advances in materials chemistry, molecular pharmaceuticsand nanobiotechnology, stimuli-responsive “smart” systems offeropportunities for precisely delivering drugs in dose-, spatial- andtemporal-controlled manners. In this talk, I will discuss our ongoingefforts in developing physiological signal-triggered bio-responsivedrug delivery systems, especially based on artificial cells orengineered cells. I will first present the glucose-responsivesynthetic systems for biomimetic delivery of insulin for diabetestreatment. Bio-responsive microneedle patches and vesiclefusion-mediated synthetic beta cells will be emphasized. I willfurther discuss the local and targeted delivery of immunomodulatorytherapeutics for enhanced cancer therapy. Our latest study utilizingplatelets and injectable gels for targeted/local delivery of immunecheckpoint inhibitors will be specifically introduced.

个人简介：

顾臻，博士，美国加州大学洛杉矶分校（UCLA）生物工程系正教授，“iMedication-智能医药实验室”主任，《NanoResearch》副主编。本科、硕士毕业于南京大学化学系及高分子科学与工程系；2010年于UCLA获得工学博士学位；同年博士后获聘于麻省理工学院化工系/Koch癌症综合研究院、哈佛大学医学院，师从RobertLanger教授。2018年前任教于北卡罗莱纳大学教堂山分校/北卡州立大学联合生物医学工程系，获评JacksonFamily杰出讲席教授。其研究方向包括蛋白质递药系统、生理响应材料、免疫治疗制剂等。目前已发表学术论文140余篇，申请专利50余项，并成立多家初创科技公司。顾臻教授曾获“斯隆研究奖”、国际药物控释学会（CRS）“青年学者奖”、美国糖尿病学会（ADA）“青年教授奖”及“Pathway”研究奖、美国生物医学工程学会（BMES）“细胞/分子生物工程创新者奖”等。《麻省理工科技评论》曾将其评为“TR35全球杰出创新者”。其发明的“智能胰岛素贴片”的研究图片曾入选《科学》杂志年度十大科技图片。

Dr.Zhen Gu is currently aFull Professor in the Department of Bioengineering at University ofCalifornia, Los Angeles (UCLA). He received B.S. degree inChemistry and M.S. degree in Polymer Chemistry and Physics fromNanjing University. In 2010, he obtained Ph.D. in the Departmentof Chemical and Biomolecular Engineering at UCLA. He was apostdoctoral associate working with Dr. Robert Langer atMIT and Harvard Medical School during 2010 to 2012. Before he movedto UCLA in 2018, he had been appointed as Jackson FamilyDistinguished Professor in the Joint Department of BiomedicalEnginering at University of North Carolina at Chapel Hill and NorthCarolina State University. Dr. Gu’s group studies controlled drugdelivery, bio-inspired materials and nanobiotechnology.  He haspublished over 140 research papers and applied over 50 patents. Hehas co-founded 3 start-up companies. He is the recipient of the SloanResearch Fellowship (2016), Young Investigator Award of theControlled Release Society (CRS) (2017), BiomaterialsScience LectureshipAward (2018), Pathway Award of the American Diabetes Association(ADA) (2015) and Young Innovator Award in Cellular and MolecularEngineering of the Biomedical Engineering Society (BMES) (2015). MITTechnology Reviewlisted him as one of the global top innovators under the age of 35(TR35). He serves as an Associate Editor for NanoResearch.